[Press release] TaiMed Biologics reports IDWeek 2026 data highlighting TMB-365 and its potential across long-acting HIV combinations
![[Press release] TaiMed Biologics reports IDWeek 2026 data highlighting TMB-365 and its potential across long-acting HIV combinations](/api/imagekit?u=https%3A%2F%2Fwww.eatg.org%2Fwp-content%2Fuploads%2F2024%2F03%2Ffbce803b-f4c4-4a5e-b693-c952d803b75e.png&w=3840&q=75)
TaiMed Biologics is presenting new clinical data at IDWeek 2026 regarding its antibody-based HIV therapy, TMB-365. The study highlights the drug's potential as a key component in long-acting HIV maintenance regimens.
Why it matters
Advancements in long-acting HIV treatments are critical for improving patient adherence and quality of life for those living with the virus.
TaiMed Biologics, a commercial-stage CD4-targeted biologics company advancing antibody-based therapies for long-acting HIV treatment, announced results from two studies to be presented at IDWeek 2026, October 21-24 in Washington, D.C. The findings highlight TMB-365’s own clinical activity and potential as a component of multiple long-acting HIV combinations, alongside laboratory evidence of complementary antiviral susceptibility supporting the company’s TMB-365/TMB-380 maintenance regimen.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in